Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8955219 | 0.86 | CA12 (0.35) | TDP1MAPK1ALDH1A1CYP3A4TSHR | |
| SCHEMBL250661 | 0.81 | IDO1 (0.43) | MAPK1ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL21162070 | 0.78 | TSHR (0.34) | TDP1MAPK1ALDH1A1CYP3A4TSHR | |
| SCHEMBL15350067 | 0.78 | TSHR (0.34) | TDP1MAPK1ALDH1A1CYP3A4TSHR | |
| SCHEMBL13450978 | 0.77 | TDP1 (0.44) | TDP1MAPK1ALDH1A1CYP3A4MAPT | |
| SCHEMBL4921245 | 0.77 | TDP1 (0.44) | TDP1MAPK1ALDH1A1CYP3A4MAPT | |
| SCHEMBL31508194 | 0.77 | TDP1 (0.44) | TDP1MAPK1ALDH1A1CYP3A4MAPT | |
| SCHEMBL2431139 | 0.76 | ACHE (0.44) | TDP1ALDH1A1CYP3A4MAPTMEN1 | |
| SCHEMBL28113583 | 0.76 | TSHR (0.31) | CYP3A4TSHR | |
| SCHEMBL28835630 | 0.75 | TDP1 (0.42) | TDP1MAPK1ALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4444313-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20200207989-A1 | FLUORESCENT PROBE FOR ALDH3A1 DETECTION | THE UNIVERSITY OF TOKYO (JP) | 2020-07-02 | — | — | US | disclosed |
| US-6518268-B1 | Telomerase inhibitors and methods of their use | GERON CORPORATION | 2003-02-11 | — | — | US | disclosed |
| WO-2001002377-A9 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORP (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-1109796-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002377-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | MLLT1, MEN1, BMI1 | TDP1 3122/4885MAPK1 629/4885ALDH1A1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.